Rigel to Present at Oppenheimer Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 5, 2013
SOUTH SAN FRANCISCO, Calif., Dec. 5, 2013 /PRNewswire/ --Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul R. Rodriguez,
the company's president and chief operations officer, is scheduled to present
a company overview at the Oppenheimer 24^th Annual Healthcare Conference in
New York City on Wednesday, December 11th at 2:10 p.m. ET.
To access the live audio webcast or the subsequent archived recording, log on
to www.rigel.com. Please connect to Rigel's website several minutes prior to
the start of the live webcast to ensure adequate time for any software
download that may be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc.is a clinical-stage drug development company that
discovers and develops novel, small-molecule drugs for the treatment of
inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's
pioneering research focuses on intracellular signaling pathways and related
targets that are critical to disease mechanisms. The Company currently has
five product candidates in development: fostamatinib, an oral SYK inhibitor
for ITP expected to enter Phase 3 clinical trials in the first half of 2014;
R348, a topical JAK/SYK inhibitor for dry eye currently in Phase 2 clinical
trials; R118, an AMPK activator entering Phase 1 in early 2014; and two
oncology product candidates in Phase 1 development with partners BerGenBio
Contact: Ryan Maynard
SOURCE Rigel Pharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.